Syndax Pharmaceuticals Inc (SNDX) — Cash Flow-to-Debt Ratio
Syndax Pharmaceuticals Inc (SNDX) has a Cash Flow-to-Debt Ratio of -0.04x as of June 2026, meaning its operating cash flow of $-30.27 Million could theoretically repay 0% of its total liabilities ($688.55 Million) in one year. See SNDX financial flexibility score to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Syndax Pharmaceuticals Inc Cash Flow-to-Debt Ratio (2011–2025)
Historical debt coverage capacity for Syndax Pharmaceuticals Inc across 15 annual periods. For the full cash flow conversion analysis, see Syndax Pharmaceuticals Inc cash flow conversion.
Annual Cash Flow-to-Debt Ratio for Syndax Pharmaceuticals Inc (2011–2025)
Year-by-year debt coverage analysis for Syndax Pharmaceuticals Inc. Check earnings quality score of Syndax Pharmaceuticals Inc to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.69x | $-322.98 Million | $465.08 Million | ▼ -10.3% |
| 2024 | -0.63x | $-274.90 Million | $436.69 Million | ▲ +77.0% |
| 2023 | -2.74x | $-160.60 Million | $58.68 Million | ▲ +39.0% |
| 2022 | -4.49x | $-133.68 Million | $29.79 Million | ▼ -736.1% |
| 2021 | 0.71x | $29.13 Million | $41.29 Million | ▲ +147.9% |
| 2020 | -1.47x | $-71.26 Million | $48.42 Million | ▲ +7.2% |
| 2019 | -1.59x | $-50.61 Million | $31.93 Million | ▲ +28.5% |
| 2018 | -2.22x | $-68.53 Million | $30.89 Million | ▼ -53.9% |
| 2017 | -1.44x | $-47.37 Million | $32.87 Million | ▼ -2.0% |
| 2016 | -1.41x | $-35.16 Million | $24.87 Million | ▼ -1250.8% |
| 2015 | -0.10x | $-2.43 Million | $23.20 Million | ▲ +86.5% |
| 2014 | -0.78x | $-14.39 Million | $18.53 Million | ▲ +44.5% |
| 2013 | -1.40x | $-7.29 Million | $5.21 Million | ▼ -364.3% |
| 2012 | -0.30x | $-9.28 Million | $30.80 Million | ▲ +28.3% |
| 2011 | -0.42x | $-10.02 Million | $23.84 Million | — |